GSK (GSK) Stock Price, News & Analysis

Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Key Stats

• Today's Range: $40.08 to $40.57
• 50-Day Range: $36.21 to $40.50
• 52-Week Range: $31.72 to $44.67
• Volume: 3.40 million shs
• Average Volume: 3.88 million shs
• Market Capitalization: $81.80 billion
• P/E Ratio: 18.59
• Dividend Yield: 4.18%
• Price Target: $37.38
• Consensus Rating: Reduce

GSK Stock Analysis - MarketRank™

GSK scored higher than 58% of companies evaluated by MarketBeat, and ranked 455th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.9 / 5
• Analyst Rating: Reduce

Consensus Rating

GSK has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

GSK has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.32%

Earnings Growth

Earnings for GSK are expected to grow by 12.32% in the coming year, from $4.14 to $4.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 18.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 18.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.15.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.62% of the float of GSK has been sold short.

Short Interest Ratio / Days to Cover

GSK has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GSK has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

GSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 77.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, GSK will have a dividend payout ratio of 36.13% next year. This indicates that GSK will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.62% of the float of GSK has been sold short.

Short Interest Ratio / Days to Cover

GSK has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GSK has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.91

News Sentiment

GSK has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for GSK this week, compared to 21 articles on an average week.

Search Interest

42 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.

MarketBeat Follows

5 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 10.00% of the stock of GSK is held by insiders.

Percentage Held by Institutions

Only 15.74% of the stock of GSK is held by institutions.

GSK Stock Analysis - Frequently Asked Questions

How have GSK shares performed this year?

GSK's stock was trading at $33.82 at the beginning of 2025. Since then, GSK shares have increased by 18.7% and is now trading at $40.1450.

How were GSK's earnings last quarter?

GSK PLC Sponsored ADR (NYSE:GSK) issued its quarterly earnings data on Wednesday, July, 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The company's revenue was up 1.3% compared to the same quarter last year.
Read the conference call transcript.

Who are GSK's major shareholders?

GSK's top institutional shareholders include Fisher Asset Management LLC (1.54%), Miller Howard Investments Inc. NY (0.08%), Douglas Lane & Associates LLC (0.06%) and Bank of New York Mellon Corp (0.05%).
View institutional ownership trends.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include Chevron (CVX), BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), Bristol Myers Squibb (BMY), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Record date for 7/10 Dividend: 5/16/2025
• Ex-Dividend for 7/10 Dividend: 5/16/2025
• Dividend Payable: 7/10/2025
• Last Earnings: 7/30/2025
• Record date for 10/9 Dividend: 8/15/2025
• Ex-Dividend for 10/9 Dividend: 8/15/2025
• Today: 8/22/2025
• Dividend Payable: 10/09/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:GSK
• CIK: 1131399
• Web: www.gsk.com
• Phone: 442080475000
• Fax: 44-20-8047-7807
• Employees: 68,629
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GSK: $37.38
• High Price Target: $39.50
• Low Price Target: $35.25
• Potential Upside/Downside: -7.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.16
• Trailing P/E Ratio: 18.66
• Forward P/E Ratio: 9.72
• P/E Growth: 1.74
• Net Income: $3.29 billion
• Net Margins: 10.81%
• Pretax Margin: 14.68%
• Return on Equity: 49.22%
• Return on Assets: 11.31%

Debt

• Debt-to-Equity Ratio: 1.07
• Current Ratio: 0.87
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: $31.63 billion
• Price / Sales: 2.59
• Cash Flow: $5.61 per share
• Price / Cash Flow: 7.18
• Book Value: $9.41 per share
• Price / Book: 4.28

Miscellaneous

• Outstanding Shares: 2,037,674,000
• Free Float: 1,833,907,000
• Market Cap: $82.04 billion
• Optionable: Optionable
• Beta: 0.51